HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19

Summary

The goal of this clinical trial Is conducted to evaluate the efficacy and safety of active or sham HD-tDCS in combination with dexmedetomidine in patients with moderate to severe ARDS due to COVID-19 with delirium in intensive care unit (ICU). The hypothesis was that HD-tDCS combined with concomitant dexmedetomidine would reduce delirium rates.

Timeline

Start

2021-04-14

Primary completion

2022-12-02

Completion

2023-01-30

Drugs

Indications